Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions
Persson, U.; Ramsberg, J.
Lakartidningen 104(42): 3046-3050
2007
ISSN/ISBN: 0023-7205 PMID: 17985712 Document Number: 607099
Document emailed within 1 workday
Related Documents
1993: An outpatient pharmacy services benefit in a reformed health care system. Coalition for Consumer Access to Pharmaceutical Care American Journal of Hospital Pharmacy 50(7): 1464-14661982: Pharmaceutical Reimbursement Board; final maximum allowable cost (MAC) determinations for certain drug products--Health Care Financing Administration. Final notice Federal Register 47(251): 58370-58372
Kennedy, D.P.; Brown, R.A.; Morrison, P.; Vie, L.; Ryan, G.W.; Tucker, J.S. 2015: Risk evaluations and condom use decisions of homeless youth: a multi-level qualitative investigation Bmc Public Health 15: 62
Greenlick, M.R. 1974: The scope and bounds of health economics and medical economics Israel Journal of Medical Sciences 10(1): 81-95
Kiely, R.G. 1993: Board backs community benefit Trustee: the journal for hospital governing boards 46(8): 13
Levoy, R.P. 1977: Three important ways a bulletin board can benefit your practice Veterinary Medicine-Small Animal Clinician 72(10): 1656-1658
Bengt, J.ön.; Arvidsson, G.ör.; Levin, L.-A.; Rehnberg, C. 2005: Drug utilization decisions should be based on cost-benefit data Lakartidningen 102(16): 1264-1265; Discussion 1265
Macdonald, R J. 2012: On the Role of Paradigms in Finance; From Economics Imperialism to Freakonomics: The Shifting Boundaries between Economics and Other Social Sciences; Economics Versus Human Rights Review of Social Economy 70(1): 134-141
Green, A.C.; Donald, G.F. 1973: The prescription of griseofulvin as a pharmaceutical benefit in South Australia Medical Journal of Australia 2(16): 760-763
Wahlstedt, K.G.I. 2002: Improved work organization can reduce health hazards. the psychosocial work environment is of great significance for both the body and the soul Lakartidningen 99(15): 1666-1670
Zych, J.; Kostka, V. 1989: The position of the Czech Pharmaceutical Society on problems in the pharmaceutical services during reconstruction of the Czechoslovak health service Ceskoslovenska Farmacie 38(5): 193-194
Burnfield, A. 1997: Interferon beta in multiple sclerosis. Reducing frequency and severity of relapses will be of great clinical benefit Bmj 314(7080): 600
Oie, S.; Frislid, K.; Waaler, T.; Arnesen, E.; Enger, E. 1971: Significance of inter-dose variation in clinical evaluations Pharmaceutica Acta Helvetiae 46(12): 702-707
Grimaldi, P.L.; Bertko, J.M. 1989: FASB (Financial Accounting Standards Board) proposal changes retiree healthcare benefit accounting Healthcare Financial Management: Journal of the Healthcare Financial Management Association 43(7): 48-9 52-4 56-7
Usman Iqbal, S.; Prashker, M. 2004: Health services research in rheumatology: a great deal accomplished, a great deal left to do Rheumatic Diseases Clinics of North America 30(4): 879-898 Viii
Knaul, F.M.; Héctor, A.-O.; Escandón, P. 2007: Competitiveness among health and the health sector. a new look at the health economics paradigm Gaceta Medica de Mexico 143(2): 93-100
Zółtowski, M.; Pilawski, Z.; Uzar, A. 1977: Significance of laparoscopy in decisions on the preventive therapy of various ovarian tumors in girls Zentralblatt für Gynakologie 99(24): 1511-1513
Lokkerbol, J.; Weehuizen, R.; Mavranezouli, I.; Mihalopoulos, C.; Smit, F. 2014: Mental health care system optimization from a health-economics perspective: where to sow and where to reap? Journal of Mental Health Policy and Economics 17(2): 51-60
Craig, N.; Walker, D. 1996: Choice and accountability in health promotion: the role of health economics Health Education Research 11(3): 355-360; Discussion: 361-366
Hale, J. 2000: What contribution can health economics make to health promotion? Health Promotion International 15(4): 341-348